Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442847 | 0.84 | TSHR (0.38) | TDP1 | |
| SCHEMBL21645577 | 0.71 | KMT2A (0.41) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL15855839 | 0.70 | KMT2A (0.31) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL25398154 | 0.67 | KMT2A (0.37) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL2430392 | 0.67 | KMT2A (0.41) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL20791160 | 0.66 | KMT2A (0.35) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL5328888 | 0.66 | KMT2A (0.40) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL3924374 | 0.66 | KMT2A (0.32) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL3543659 | 0.65 | SMN1; SMN2 (0.40) | KMT2AMEN1APEX1TDP1L3MBTL1 | |
| SCHEMBL5051973 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124944-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-12-02 | — | — | EP | claimed |
| WO-2008111010-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-18 | — | — | WO | claimed |
| US-7981883-B2 | Substituted spiro-compounds and the use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | REN, PKD1, PKD2 | KMT2A 3763/4885MEN1 596/4885APEX1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.